Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H18O3 |
| Molecular Weight | 246.3016 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@]3(C)O[C@@]34CC=C(C)[C@]4([H])[C@@]1([H])OC(=O)C2=C
InChI
InChIKey=UVJYAKBJSGRTHA-CUZKYEQNSA-N
InChI=1S/C15H18O3/c1-8-4-7-15-11(8)12-10(9(2)13(16)17-12)5-6-14(15,3)18-15/h4,10-12H,2,5-7H2,1,3H3/t10-,11+,12-,14-,15+/m0/s1
| Molecular Formula | C15H18O3 |
| Molecular Weight | 246.3016 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:43:49 GMT 2023
by
admin
on
Sat Dec 16 11:43:49 GMT 2023
|
| Record UNII |
YS8UOP7QZ1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
YS8UOP7QZ1
Created by
admin on Sat Dec 16 11:43:49 GMT 2023 , Edited by admin on Sat Dec 16 11:43:49 GMT 2023
|
PRIMARY | |||
|
84692-91-1
Created by
admin on Sat Dec 16 11:43:49 GMT 2023 , Edited by admin on Sat Dec 16 11:43:49 GMT 2023
|
PRIMARY | |||
|
Arglabin
Created by
admin on Sat Dec 16 11:43:49 GMT 2023 , Edited by admin on Sat Dec 16 11:43:49 GMT 2023
|
PRIMARY | |||
|
73228
Created by
admin on Sat Dec 16 11:43:49 GMT 2023 , Edited by admin on Sat Dec 16 11:43:49 GMT 2023
|
PRIMARY | |||
|
DTXSID30233687
Created by
admin on Sat Dec 16 11:43:49 GMT 2023 , Edited by admin on Sat Dec 16 11:43:49 GMT 2023
|
PRIMARY | |||
|
5574924
Created by
admin on Sat Dec 16 11:43:49 GMT 2023 , Edited by admin on Sat Dec 16 11:43:49 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
It is found in Artemisia glabella. Arglabin-DMA HCl, the hydrochloride salt of the adduct resulting from the conjugate addition of dimethylamine to the ene-lactone moiety, has been successfully used in Khazakhstan for the treatment of breast, colon, ovarian and lung cancers.
|
||
|
ACTIVE MOIETY |
Arglabin reduces inflammation, plasma lipids, increases autophagy, and orients tissue macrophages into an anti-inflammatory phenotype in ApoE2.Ki mice fed a HFD. Consequently, a marked reduction of atherosclerotic lesions was observed. Thus, arglabin may represent a new promising drug to treat inflammation and atherosclerosis.
|
||
|
ACTIVE MOIETY |
Semi-synthetic from parthenolide (AG-CN2-0455), which is isolated from Magnolia grandiflora.
|
